| Title: |
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma |
| Authors: |
Mateos M. -V.; Weisel K.; De Stefano V.; Goldschmidt H.; Delforge M.; Mohty M.; Cavo M.; Vij R.; Lindsey-Hill J.; Dytfeld D.; Angelucci E.; Perrot A.; Benjamin R.; van de Donk N. W. C. J.; Ocio E. M.; Scheid C.; Gay F.; Roeloffzen W.; Rodriguez-Otero P.; Broijl A.; Potamianou A.; Sakabedoyan C.; Semerjian M.; Keim S.; Strulev V.; Schecter J. M.; Vogel M.; Wapenaar R.; Nesheiwat T.; San-Miguel J.; Sonneveld P.; Einsele H.; Moreau P. |
| Contributors: |
Mateos M.-V.; Weisel K.; De Stefano V.; Goldschmidt H.; Delforge M.; Mohty M.; Cavo M.; Vij R.; Lindsey-Hill J.; Dytfeld D.; Angelucci E.; Perrot A.; Benjamin R.; van de Donk N.W.C.J.; Ocio E.M.; Scheid C.; Gay F.; Roeloffzen W.; Rodriguez-Otero P.; Broijl A.; Potamianou A.; Sakabedoyan C.; Semerjian M.; Keim S.; Strulev V.; Schecter J.M.; Vogel M.; Wapenaar R.; Nesheiwat T.; San-Miguel J.; Sonneveld P.; Einsele H.; Moreau P. |
| Publication Year: |
2022 |
| Collection: |
IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
| Subject Terms: |
LocoMMotion; relapsed; refractory; multiple myeloma |
| Description: |
Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed/refractory MM (RRMM). Patients (N = 248; ECOG performance status of 0–1, ≥3 prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1–20) cycles of SOC therapy. Overall response rate was 29.8% (95% CI: 24.2–36.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95% CI: 3.9–5.6) and 12.4 months (95% CI: 10.3–NE). Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3/4). Altogether, 107 deaths occurred, due to progressive disease (n = 74), TEAEs (n = 19), and other reasons (n = 14). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action. |
| Document Type: |
article in journal/newspaper |
| File Description: |
STAMPA |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/35332278; info:eu-repo/semantics/altIdentifier/wos/WOS:000772959300001; volume:36; issue:5; firstpage:1371; lastpage:1376; numberofpages:6; journal:LEUKEMIA; https://hdl.handle.net/11585/903522 |
| DOI: |
10.1038/s41375-022-01531-2 |
| Availability: |
https://hdl.handle.net/11585/903522; https://doi.org/10.1038/s41375-022-01531-2; https://www.nature.com/articles/s41375-022-01531-2 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.524E93CF |
| Database: |
BASE |